Diagnosis and Management of Small Choroidal Melanoma

  • Amy C. ScheflerEmail author
  • Ryan Sangwoo Kim
Part of the Current Practices in Ophthalmology book series (CUPROP)


Uveal melanoma is the most common primary ocular cancer in adults. Key advancements have been made over the past decade in terms of molecularly classifying uveal melanoma and maximizing treatment outcomes of plaque brachytherapy. Also, various targeted immunotherapies are currently being investigated as adjuvant and metastatic treatments for uveal melanoma.


Uveal Melanoma Gene expression profile Brachytherapy Prognostic information PRAME Fine-needle aspiration biopsy Histopathology 


  1. 1.
    Hu DN, Yu GP, McCormick SA, Schneider S, Finger PT. Population-based incidence of uveal melanoma in various races and ethnic groups. Am J Ophthalmol. 2005;140(4):612–7. Scholar
  2. 2.
    Dogrusoz M, Jager MJ, Damato B. Uveal melanoma treatment and prognostication. Asia Pac J Ophthalmol. 2017;6(2):186–96. Scholar
  3. 3.
    Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119(5):670–6.CrossRefGoogle Scholar
  4. 4.
    Diener-West M, Reynolds SM, Agugliaro DJ, Caldwell R, Cumming K, Earle JD, Hawkins BS, Hayman JA, Jaiyesimi I, Jampol LM, Kirkwood JM, Koh WJ, Robertson DM, Shaw JM, Straatsma BR, Thoma J, Collaborative Ocular Melanoma Study Group. Development of metastatic disease after enrollment in the COMS trials for treatment of choroidal melanoma: Collaborative Ocular Melanoma Study Group report no. 26. Arch Ophthalmol. 2005;123(12):1639–43. Scholar
  5. 5.
    Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, Schachat AP, Straatsma BR, Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS report no. 18. Arch Ophthalmol. 2001;119(7):969–82.PubMedCrossRefGoogle Scholar
  6. 6.
    Kujala E, Makitie T, Kivela T. Very long-term prognosis of patients with malignant uveal melanoma. Invest Ophthalmol Vis Sci. 2003;44(11):4651–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Chew AL, Spilsbury K, Isaacs TW. Survival from uveal melanoma in Western Australia 1981-2005. Clin Exp Ophthalmol. 2015;43(5):422–8. Scholar
  8. 8.
    Shields CL, Furuta M, Thangappan A, Nagori S, Mashayekhi A, Lally DR, Kelly CC, Rudich DS, Nagori AV, Wakade OA, Mehta S, Forte L, Long A, Dellacava EF, Kaplan B, Shields JA. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127(8):989–98. Scholar
  9. 9.
    Costache M, Patrascu OM, Adrian D, Costache D, Sajin M, Ungureanu E, Simionescu O. Ciliary body melanoma—a particularly rare type of ocular tumor. Case report and general considerations. Maedica (Buchar). 2013;8(4):360–4.Google Scholar
  10. 10.
    Shields CL, Kaliki S, Furuta M, Mashayekhi A, Shields JA. Clinical spectrum and prognosis of uveal melanoma based on age at presentation in 8,033 cases. Retina. 2012;32(7):1363–72. Scholar
  11. 11.
    Kaliki S, Shields CL, Mashayekhi A, Ganesh A, Furuta M, Shields JA. Influence of age on prognosis of young patients with uveal melanoma: a matched retrospective cohort study. Eur J Ophthalmol. 2013;23(2):208–16. Scholar
  12. 12.
    Onken MD, Worley LA, Ehlers JP, Harbour JW. Gene expression profiling in uveal melanoma reveals two molecular classes and predicts metastatic death. Cancer Res. 2004;64(20):7205–9. Scholar
  13. 13.
    Field MG, Harbour JW. Recent developments in prognostic and predictive testing in uveal melanoma. Curr Opin Ophthalmol. 2014;25(3):234–9. Scholar
  14. 14.
    Shields CL, Kels JG, Shields JA. Melanoma of the eye: revealing hidden secrets, one at a time. Clin Dermatol. 2015;33(2):183–96. Scholar
  15. 15.
    The Collaborative Ocular Melanoma Study Group. Factors predictive of growth and treatment of small choroidal melanoma: COMS report no. 5. Arch Ophthalmol. 1997;115(12):1537–44.CrossRefGoogle Scholar
  16. 16.
    Nguyen BT, Kim RS, Bretana ME, Kegley E, Schefler AC. Association between traditional clinical high-risk features and gene expression profile classification in uveal melanoma. Graefes Arch Clin Exp Ophthalmol. 2018;256(2):421–7. Scholar
  17. 17.
    Kim RS, Chevez-Barrios P, Bretana ME, Wong TP, Teh BS, Schefler AC. Histopathologic analysis of transvitreal fine needle aspiration biopsy needle tracts for uveal melanoma. Am J Ophthalmol. 2017;174:9–16. Scholar
  18. 18.
    Schefler AC, Gologorsky D, Marr BP, Shields CL, Zeolite I, Abramson DH. Extraocular extension of uveal melanoma after fine-needle aspiration, vitrectomy, and open biopsy. JAMA Ophthalmol. 2013;131(9):1220–4. Scholar
  19. 19.
    Singh AD, Medina CA, Singh N, Aronow ME, Biscotti CV, Triozzi PL. Fine-needle aspiration biopsy of uveal melanoma: outcomes and complications. Br J Ophthalmol. 2016;100(4):456–62. Scholar
  20. 20.
    Shields CL, Ganguly A, Materin MA, Teixeira L, Mashayekhi A, Swanson LA, Marr BP, Shields JA. Chromosome 3 analysis of uveal melanoma using fine-needle aspiration biopsy at the time of plaque radiotherapy in 140 consecutive cases: the Deborah Iverson, MD, Lectureship. Arch Ophthalmol. 2007;125(8):1017–24. Scholar
  21. 21.
    Correa ZM, Augsburger JJ. Sufficiency of FNAB aspirates of posterior uveal melanoma for cytologic versus GEP classification in 159 patients, and relative prognostic significance of these classifications. Graefes Arch Clin Exp Ophthalmol. 2014;252(1):131–5. Scholar
  22. 22.
    Kim RS, Chevez-Barrios P, Divatia M, Bretana ME, Teh BS, Schefler AC. Transvitreal and transscleral biopsies in small uveal melanoma: report on yield, techniques, and complications. JAMA Ophthalmol. 2018;2(4):208–12.Google Scholar
  23. 23.
    Melia BM, Abramson DH, Albert DM, Boldt HC, Earle JD, Hanson WF, Montague P, Moy CS, Schachat AP, Simpson ER, Straatsma BR, Vine AK, Weingeist TA, Collaborative Ocular Melanoma Study Group. Collaborative ocular melanoma study (COMS) randomized trial of I-125 brachytherapy for medium choroidal melanoma. I. Visual acuity after 3 years COMS report no. 16. Ophthalmology. 2001;108(2):348–66.PubMedCrossRefGoogle Scholar
  24. 24.
    American Brachytherapy Society–Ophthalmic Oncology Task Force. Electronic Address Pec, Committee AO. The American Brachytherapy Society consensus guidelines for plaque brachytherapy of uveal melanoma and retinoblastoma. Brachytherapy. 2014;13(1):1–14. Scholar
  25. 25.
    Nag S, Quivey JM, Earle JD, Followill D, Fontanesi J, Finger PT, American Brachytherapy S. The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys. 2003;56(2):544–55.PubMedCrossRefGoogle Scholar
  26. 26.
    Astrahan MA, Luxton G, Pu Q, Petrovich Z. Conformal episcleral plaque therapy. Int J Radiat Oncol Biol Phys. 1997;39(2):505–19.PubMedCrossRefGoogle Scholar
  27. 27.
    King B, Morales-Tirado VM, Wynn HG, Gao BT, Ballo MT, Wilson MW. Repeat episcleral plaque brachytherapy: clinical outcomes in patients treated for locally recurrent posterior uveal melanoma. Am J Ophthalmol. 2017;176:40–5. Scholar
  28. 28.
    Aziz HA, Al Zahrani YA, Bena J, Lorek B, Wilkinson A, Suh J, Singh AD. Episcleral brachytherapy of uveal melanoma: role of intraoperative echographic confirmation. Br J Ophthalmol. 2017;101(6):747–51. Scholar
  29. 29.
    Tabandeh H, Chaudhry NA, Murray TG, Ehlies F, Hughes R, Scott IU, Markoe AM. Intraoperative echographic localization of iodine-125 episcleral plaque for brachytherapy of choroidal melanoma. Am J Ophthalmol. 2000;129(2):199–204.PubMedCrossRefGoogle Scholar
  30. 30.
    Mruthyunjaya P, Seider MI, Stinnett S, Schefler A, Ocular Oncology Study Consortium. Association between tumor regression rate and gene expression profile after iodine 125 plaque radiotherapy for uveal melanoma. Ophthalmology. 2017;124(10):1532–9. Scholar
  31. 31.
    Ophthalmic Oncology Task Force. Local recurrence significantly increases the risk of metastatic uveal melanoma. Ophthalmology. 2016;123(1):86–91. Scholar
  32. 32.
    Force OOT. Local recurrence significantly increases the risk of metastatic uveal melanoma. Ophthalmology. 2016;123(1):86–91. Scholar
  33. 33.
    Collaborative Ocular Melanoma Study Group. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma: V. Twelve-year mortality rates and prognostic factors: COMS report No. 28. Arch Ophthalmol. 2006;124(12):1684–93. Scholar
  34. 34.
    Berry JL, Dandapani SV, Stevanovic M, Lee TC, Astrahan M, Murphree AL, Kim JW. Outcomes of choroidal melanomas treated with eye physics: a 20-year review. JAMA Ophthalmol. 2013;131(11):1435–42. Scholar
  35. 35.
    Tann AW, Teh BS, Scarboro SB, Lewis GD, Bretana ME, Croft PC, Raizen Y, Butler EB, Kim RS, Chevez-Barrios P, Schefler AC. Early outcomes of uveal melanoma treated with intraoperative ultrasound guided brachytherapy using custom built plaques. Pract Radiat Oncol. 2017;7(4):e275–82. Scholar
  36. 36.
    McCannel TA, Chang MY, Burgess BL. Multi-year follow-up of fine-needle aspiration biopsy in choroidal melanoma. Ophthalmology. 2012;119(3):606–10. Scholar
  37. 37.
    Seibel I, Cordini D, Rehak M, Hager A, Riechardt AI, Boker A, Heufelder J, Weber A, Gollrad J, Besserer A, Joussen AM. Local recurrence after primary proton beam therapy in uveal melanoma: risk factors, retreatment approaches, and outcome. Am J Ophthalmol. 2015;160(4):628–36. Scholar
  38. 38.
    Desjardins L, Lumbroso L, Levy C, Mazal A, Delacroix S, Rosenwald JC, Dendale R, Plancher C, Asselain B. Treatment of uveal melanoma with iodine 125 plaques or proton beam therapy: indications and comparison of local recurrence rates. J Fr Ophthalmol. 2003;26(3):269–76.Google Scholar
  39. 39.
    Pereira PR, Odashiro AN, Lim LA, Miyamoto C, Blanco PL, Odashiro M, Maloney S, De Souza DF, Burnier MN Jr. Current and emerging treatment options for uveal melanoma. Clin Ophthalmol. 2013;7:1669–82. Scholar
  40. 40.
    Finger PT, Chin KJ, Semenova EA. Intravitreal anti-VEGF therapy for macular radiation retinopathy: a 10-year study. Eur J Ophthalmol. 2016;26(1):60–6. Scholar
  41. 41.
    Mashayekhi A, Rojanaporn D, Al-Dahmash S, Shields CL, Shields JA. Monthly intravitreal bevacizumab for macular edema after iodine-125 plaque radiotherapy of uveal melanoma. Eur J Ophthalmol. 2014;24(2):228–34. Scholar
  42. 42.
    Kim IK, Lane AM, Jain P, Awh C, Gragoudas ES. Ranibizumab for the prevention of radiation complications in patients treated with proton beam irradiation for choroidal melanoma. Trans Am Ophthalmol Soc. 2016;114:T2.PubMedPubMedCentralGoogle Scholar
  43. 43.
    Komatsubara KM, Carvajal RD. Immunotherapy for the treatment of uveal melanoma: current status and emerging therapies. Curr Oncol Rep. 2017;19(7):45. Scholar
  44. 44.
    Triozzi PL, Singh AD. Adjuvant therapy of uveal melanoma: current status. Ocul Oncol Pathol. 2014;1(1):54–62. Scholar
  45. 45.
    Lane AM, Egan KM, Harmon D, Holbrook A, Munzenrider JE, Gragoudas ES. Adjuvant interferon therapy for patients with uveal melanoma at high risk of metastasis. Ophthalmology. 2009;116(11):2206–12. Scholar
  46. 46.
    Jager MJ, Dogrusoz M, Woodman SE. Uveal melanoma: identifying immunological and chemotherapeutic targets to treat metastases. Asia Pac J Ophthalmol. 2017;6(2):179–85. Scholar
  47. 47.
    Luke JJ, Callahan MK, Postow MA, Romano E, Ramaiya N, Bluth M, Giobbie-Hurder A, Lawrence DP, Ibrahim N, Ott PA, Flaherty KT, Sullivan RJ, Harding JJ, D’Angelo S, Dickson M, Schwartz GK, Chapman PB, Wolchok JD, Hodi FS, Carvajal RD. Clinical activity of ipilimumab for metastatic uveal melanoma: a retrospective review of the Dana-Farber Cancer Institute, Massachusetts General Hospital, Memorial Sloan-Kettering Cancer Center, and University Hospital of Lausanne experience. Cancer. 2013;119(20):3687–95. Scholar
  48. 48.
    Algazi AP, Tsai KK, Shoushtari AN, Munhoz RR, Eroglu Z, Piulats JM, Ott PA, Johnson DB, Hwang J, Daud AI, Sosman JA, Carvajal RD, Chmielowski B, Postow MA, Weber JS, Sullivan RJ. Clinical outcomes in metastatic uveal melanoma treated with PD-1 and PD-L1 antibodies. Cancer. 2016;122(21):3344–53. Scholar
  49. 49.
    Field MG, Decatur CL, Kurtenbach S, Gezgin G, van der Velden PA, Jager MJ, Kozak KN, Harbour JW. PRAME as an independent biomarker for metastasis in uveal melanoma. Clin Cancer Res. 2016;22(5):1234–42. Scholar
  50. 50.
    Gezgin G, Luk SJ, Cao J, Dogrusoz M, van der Steen DM, Hagedoorn RS, Krijgsman D, van der Velden PA, Field MG, Luyten GPM, Szuhai K, Harbour JW, Jordanova ES, Heemskerk MHM, Jager MJ. PRAME as a potential target for immunotherapy in metastatic uveal melanoma. JAMA Ophthalmol. 2017;135(6):541–9. Scholar
  51. 51.
    Kines RC, Varsavsky I, Choudhary S, Bhattacharya D, Spring S, McLaughlin RJ, Kang SJ, Grossniklaus HE, Vavvas DG, Monks S, MacDougall JR, de Los Pinos E, Schiller JT. An infrared dye-conjugated virus-like particle for the treatment of primary uveal melanoma. Mol Cancer Ther. 2018;17(2):565–74. Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2019

Authors and Affiliations

  1. 1.Retina Consultants of Houston, Blanton Eye InstituteHouston Methodist HospitalHoustonUSA
  2. 2.Children’s Memorial Hermann HospitalUniversity of Texas Health SciencesSan AntonioUSA

Personalised recommendations